Octagon Capital Advisors LP Sells 6,165,371 Shares of Gossamer Bio, Inc. $GOSS

Octagon Capital Advisors LP decreased its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 44.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,750,000 shares of the company’s stock after selling 6,165,371 shares during the period. Gossamer Bio accounts for 0.3% of Octagon Capital Advisors LP’s portfolio, making the stock its 29th largest position. Octagon Capital Advisors LP owned approximately 3.30% of Gossamer Bio worth $2,546,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GOSS. Legal & General Group Plc bought a new stake in shares of Gossamer Bio in the 2nd quarter worth approximately $26,000. Banco BTG Pactual S.A. bought a new position in Gossamer Bio during the 2nd quarter valued at approximately $27,000. Soltis Investment Advisors LLC purchased a new position in Gossamer Bio during the fourth quarter valued at $31,000. MMA Asset Management LLC purchased a new position in Gossamer Bio during the fourth quarter valued at $31,000. Finally, Beacon Pointe Advisors LLC bought a new stake in Gossamer Bio in the fourth quarter worth $34,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of GOSS opened at $0.14 on Monday. Gossamer Bio, Inc. has a twelve month low of $0.11 and a twelve month high of $3.87. The company has a market capitalization of $31.92 million, a P/E ratio of -0.17 and a beta of 2.04. The firm has a 50 day moving average of $0.18 and a 200 day moving average of $0.81.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $16.95 million during the quarter, compared to analyst estimates of $4.67 million. On average, sell-side analysts expect that Gossamer Bio, Inc. will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GOSS shares. Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. HC Wainwright dropped their price target on shares of Gossamer Bio from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.20.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.